| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 158.3 | 182.3 | 124.9 |
| Other income | 5.4 | 6.4 | 5.2 |
| Total income | 163.7 | 188.8 | 130.1 |
| Profit before exceptional items & tax | 54.3 | 62.7 | 44.1 |
| Profit before tax | 54.3 | 62.7 | 44.1 |
| Net profit | 40.6 | 48.5 | 31.3 |
| Operating margin | 33.2% | 33.2% | 33.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +29.70% |
|---|---|
| Net profit, quarter on quarter | -16.30% |
| Revenue, year on year | +26.70% |
| Operating profit, year on year | +25.70% |
| Operating profit, quarter on quarter | -13.10% |
NSE results filing, NSE: SUDEEPPHRM. Figures extracted from the filing.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,175.00
- Market cap
- ₹13,271 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.7×Sector 47.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Other Announcement
Sudeep Pharma Limited corrected a clerical error regarding the number of attendees at its Annual General Meeting, updating the count from 45 to 44.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Annual General Meeting
Sudeep Pharma Limited held its 37th Annual General Meeting on August 4, 2026. The meeting transacted business including financial statement approval, director appointments, dividend declaration, and ESOP schemes.
Sudeep Pharma Capital Structure Change
Nuvama Crossover Opportunities Funds reduced their stake in Sudeep Pharma Ltd. The promoter field is 'No', indicating a non-promoter equity transaction.
Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.